Peptide library
Fat Loss

AOD-9604

Fragment of hGH (176-191) studied in lipid metabolism research.

Mechanism Focused

Evidence Level

Low

Mechanism5/10
Safety Clarity6/10
Research Popularity5/10

Research Type

AnimalHuman

/ System Mapping

Where this compound appears in research pathways

Research-only note: This mapping is educational and does not represent a treatment protocol.

/ 01

Overview

Fragment of hGH (176-191) studied in lipid metabolism research.

/ 02

Mechanism of Action

Studied for lipolytic signaling without GH-like growth effects.

/ 03

Research Applications

Fat oxidation pathway research.

Studied for, research explores, preclinical models suggest, clinical studies have investigated.

/ 04

Studied Research Contexts

AnimalHuman

/ 05

Studied Research Dosing Ranges

Limited public data on dosing ranges across research models.

Dosing varies by study design and is not a recommendation for human use.

/ 06

Potential Adverse Effects Reported in Research

Adverse effect data is limited. Many compounds in this database lack human safety profiles.

/ 07

Mechanism Deep Dive

AOD-9604 is a fragment derived from the C-terminus of human growth hormone. Preclinical research describes interactions with lipolytic signaling and beta-adrenergic pathways, with reported effects on fat oxidation in animal models.

/ 08

Pathway Role

Sits within lipid metabolism and adrenergic signaling pathways at the adipocyte level in preclinical models.

/ 09

Biological Targets

Beta-3 adrenergic receptor signaling (preclinical)Lipolytic signaling pathwaysFat oxidation enzymes (preclinical)

/ 10

Research Applications

  • Preclinical obesity and lipid metabolism studies
  • Adipose tissue signaling research

/ 11

Evidence Summary

Animal data provides the strongest mechanistic signal. Human outcome data is weak or mixed.

Evidence Level Rationale

Rated low because human clinical outcome trials have not consistently supported the preclinical lipolytic signal.

/ 12

Research Observation Timeline

Early Signal Window

Acute lipolytic markers in animal models within days

Primary Study Window

Preclinical studies often used short windows (e.g. 14 days in obese mice)

Endpoint Type

Biomarker and adipose tissue endpoints

Evidence Strength

Low / mixed for human outcomes

Human clinical support is weak/mixed. A confident outcome timeline is not justified.

/ 13

Safety & Unknowns

Limited human safety data. Long-term human outcome and safety profile is not characterized.

/ 14

Research Limitations

Reliance on short rodent studies. Translation to human body composition outcomes is not established.

/ 15

References

References are being curated from peer-reviewed literature.

/ 07

Evidence Score

Mechanism Confidence5/10
Safety Clarity6/10
Research Popularity5/10

Overall Research Confidence

Low

Reflects breadth of mechanism, study type, and reproducibility across research literature.

For research and educational purposes only.

Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.